In vivo Hemostatic Activity of Jatropha mollissima: A Triple-Blinded, Randomized, Controlled Trial in an Animal Model.

The objective of this study was to evaluate the hemostatic activity of the sap from Jatropha mollissima (Pohl) Baill. in rats.
Twenty-four Wistar rats were randomized into four groups (n = 6): the JM25 and JM40 groups were treated with ethanolic extract from the sap of J. mollissima, in a concentration of 25 and 40 mg·mL1, respectively; the MO group was treated with Monsel's solution and the control group SC with a 0.9% sodium chloride solution.
Data were submitted to the Kurskal-Wallis' test, followed by Dunn's post hoc (p < 0.05).
There was a significant reduction in the bleeding time of the group from the JM25 extract (p = 0.001) when compared with MO and SC. There were no statistically significant differences between groups JM25 and JM40 (p > 0.05). The JM25 group did not present rebleeding, a result significantly different from the MO group (p = 0.001). Monsel's solution showed significant bleeding, six times greater than the control group SC.
The J. mollissima extract, in the concentration of 25 mg·mL1, showed the highest hemostatic efficiency and was found to be a promising biomaterial for the elaboration of a hemostatic product.
AuthorsMaria Vitoria Oliveira Dantas, Paula Lima Nogueira, Filipe de Oliveira Lima, Denis Candeia Pereira Oliveira, Emanuelly Nara Severiano Gomes, José Filipe Bacalhau Rodrigues, Solomon Kweku Sagoe Amoah, Rosana Araújo Rosendo, Elizandra Silva da Penha, Antonio Flávio Medeiros Dantas, Marcus Vinícius Lia Fook, Rogério Lacerda-Santos, Luanna Abílio Diniz Melquiades de Medeiros
JournalEuropean journal of dentistry (Eur J Dent) Vol. 15 Issue 4 Pg. 741-745 (Oct 2021) ISSN: 1305-7456 [Print] Germany
PMID34428842 (Publication Type: Journal Article)
CopyrightEuropean Journal of Dentistry. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: